Eli Lilly and Company (Respondent) v Actavis UK Limited and others (Appellants)
Case ID: UKSC 2015/0181
Whether a new pemetrexed based cancer treatment produced by Actavis UK Limited and others infringes Eli Lilly and Company’s patent and its foreign designations either indirectly under s. 60(2) of the Patents Act 1977 (matter for appeal) or directly under a proper interpretation of Article 69 of the Europe Patent Convention 2000 (matter for cross-appeal).
In order to market a new cancer treatment product, Actavis UK Limited and others applied for declarations of non-infringements of a European patent owned by Eli Lilly and Company and registered in the UK and the corresponding national designations in France, Italy and Spain.
Actavis UK Limited and others
Eli Lilly and Company
Lord Neuberger, Lord Mance, Lord Clarke, Lord Sumption, Lord Hodge
Hearing start date
04 Apr 2017
Hearing finish date
06 Apr 2017
|04 Apr 2017||Morning session||Afternoon session|
|05 Apr 2017||Morning session||Afternoon session|
|06 Apr 2017||Morning session||Afternoon session|